We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+50.91%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$388M
AUM Growth
-$19.7M
Cap. Flow
-$118M
Cap. Flow %
-30.34%
Top 10 Hldgs %
28.14%
Holding
181
New
33
Increased
26
Reduced
86
Closed
36

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$6.38M
2
MAZE
Maze Therapeutics
MAZE
+$5.85M
3
TERN
Terns Pharmaceuticals
TERN
+$4.05M
4
PHVS icon
Pharvaris
PHVS
+$3.91M
5
STOK icon
Stoke Therapeutics
STOK
+$3.47M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$12.9M
2
MRUS
Merus
MRUS
+$12.6M
3
ABVX
Abivax
ABVX
+$12.3M
4
SNDK
Sandisk
SNDK
+$8.63M
5
DBC icon
Invesco DB Commodity Index Tracking Fund
DBC
+$8.61M

Sector Composition

Rank Sector Weight
1 Healthcare 69.79%
2 Technology 6.85%
3 Industrials 5.94%
4 Financials 3.09%
5 Consumer Discretionary 2.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBC icon
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.69B
$23.6M 6.09%
1,057,238
-378,898
-26% -$8.61M
GPCR icon
2
Structure Therapeutics
GPCR
$3.52B
$13.4M 3.46%
193,001
-43,235
-18% -$1.77M
COGT icon
3
Cogent Biosciences
COGT
$7.07B
$12M 3.08%
336,667
-125,738
-27% -$3.53M
VRDN icon
4
Viridian Therapeutics
VRDN
$2.2B
$11.6M 2.99%
372,472
-96,863
-21% -$2.66M
ABVX
5
Abivax
ABVX
$10.8B
$9.73M 2.51%
72,185
-112,283
-61% -$12.3M
RVMD icon
6
Revolution Medicines
RVMD
$40.9B
$9.58M 2.47%
120,240
-55,208
-31% -$3.62M
PRAX icon
7
Praxis Precision Medicines
PRAX
$8.58B
$7.62M 1.96%
25,841
-69,161
-73% -$12.9M
NUVL
8
DELISTED
Nuvalent
NUVL
$7.37M 1.9%
73,287
-20,007
-21% -$1.97M
CYTK icon
9
Cytokinetics
CYTK
$10.9B
$7.28M 1.87%
114,564
-18,366
-14% -$1.14M
TERN
10
DELISTED
Terns Pharmaceuticals
TERN
$7.09M 1.83%
+175,462
New +$4.05M
MAZE
11
Maze Therapeutics
MAZE
$1.53B
$7.06M 1.82%
+170,353
New +$5.85M
INSM icon
12
Insmed
INSM
$22B
$6.86M 1.77%
39,400
-10,549
-21% -$1.92M
APGE icon
13
Apogee Therapeutics
APGE
$10.2B
$6.74M 1.73%
89,229
-17,878
-17% -$1.13M
PTGX icon
14
Protagonist Therapeutics
PTGX
$8.92B
$6.42M 1.65%
73,545
-48,137
-40% -$3.94M
SLNO
15
DELISTED
Soleno Therapeutics
SLNO
$6.25M 1.61%
135,069
+116,369
+622% +$6.38M
SYRE icon
16
Spyre Therapeutics
SYRE
$8.81B
$6.17M 1.59%
188,206
-27,540
-13% -$720K
BBIO icon
17
BridgeBio Pharma
BBIO
$16.1B
$6.13M 1.58%
80,205
-1,754
-2% -$115K
OLMA icon
18
Olema Pharmaceuticals
OLMA
$1.03B
$6.04M 1.55%
241,489
-195,690
-45% -$3.48M
IMVT icon
19
Immunovant
IMVT
$8.11B
$5.64M 1.45%
221,883
-31,244
-12% -$697K
LQDA icon
20
Liquidia Corp
LQDA
$7.72B
$5.38M 1.39%
156,003
-20,482
-12% -$583K
PCVX icon
21
Vaxcyte
PCVX
$8.08B
$5.26M 1.36%
114,049
+27,247
+31% +$1.22M
CDTX
22
DELISTED
Cidara Therapeutics
CDTX
$5.06M 1.3%
22,928
-47,976
-68% -$7.75M
ACLX
23
DELISTED
Arcellx
ACLX
$4.89M 1.26%
75,002
-21,175
-22% -$1.69M
RLAY icon
24
Relay Therapeutics
RLAY
$4.24B
$4.61M 1.19%
545,079
+304,620
+127% +$2.17M
RYTM icon
25
Rhythm Pharmaceuticals
RYTM
$7.25B
$4.59M 1.18%
42,867
+5,385
+14% +$571K
1
2 3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return

HighVista Strategies's Q4 2025 Portfolio in Review

As of Q4 2025, HighVista Strategies held 181 positions worth $388M, down 4.8% from $408M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies withdrew a net $118M in Q4 2025, closing 36 positions and reducing 86 holdings. Its most notable exit was Merus, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 59% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Maze Therapeutics worth $7.06M.

  • HighVista Strategies's largest Q4 2025 buy was Maze Therapeutics: 170,353 shares worth $7.06M.
  • HighVista Strategies added most to Soleno Therapeutics in Q4 2025, an estimated $6.38M increase.
  • HighVista Strategies's biggest Q4 2025 reduction was Praxis Precision Medicines, cutting an estimated $12.9M.
  • HighVista Strategies fully exited Merus in Q4 2025, selling an estimated $12.6M.
  • HighVista Strategies's ten largest holdings make up 28% of its $388M portfolio in Q4 2025.
  • HighVista Strategies opened 33 new positions and closed 36 in Q4 2025.
  • HighVista Strategies's portfolio value fell 4.8% quarter-over-quarter to $388M.

Based on HighVista Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.